Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves

• Status: Unknown status
• Trial end date: 2020-06-01
• Target enrollment: 0
• Participant gender: All

Summary

After implantation of an Ahmed glaucoma valve in patients with glaucoma, hyperencapsulation phase is an unwanted postoperative phenomenon, typically occurring with the free 3 months postoperatively. When this does occur, it is treated with aqueous suppressant eye drops.

This study aims to determine if it is possible to reduce the rate of hyperencapsulation phase. Patients in the treatment group will receive aqueous suppressant eye drops before the hyperencapsulation phase starts. Treatment will be initiated once their intraocular pressure is above a pre-defined level, and will target a pre-defined range.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Credit Valley EyeCare
• Collaborator: Canadian Glaucoma Clinical Research Council
• Treatments: Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Ophthalmic Solutions; Tetrahydrozoline; Travoprost

Criteria

Inclusion Criteria:

• clinical diagnosis of glaucoma

• scheduled for Ahmed glaucoma valve surgery, with or without simultaneous cataract surgery

Exclusion Criteria:

• neovascular glaucoma

• uveitic glaucoma

• prior tube shunt surgery

• prior cyclodestruction procedure

• abnormal cornea that would make IOP measurements unreliable

• sulfa allergy

• systemic contraindication to acetazolamide use

• inability to attend follow up visits

• intraocular pressure greater than 21 at postoperative week 1 (represents primary failure of the valve)

• anterior chamber fill within the first week postoperatively